Jami Rubin - 19 Aug 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)

Footnote F1

The stock option vested as to 25% of the underlying shares in connection with the consummation of the Issuer's initial public offering, and vests as to the remaining underlying shares in 36 substantially equal monthly installments beginning on August 31, 2024.

Footnote F2

On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged.

Footnote F3

The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024.

Footnote F4

The stock option vests in 48 substantially equal monthly `installments beginning on April 27, 2024.

Footnote F5

The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability.